Critical Care Market to 2019 - Growth from Factor Concentrates, New Indications and Increasing Demand for Albumin in Asia-Pacific


#167891

N/A

GBI Research

$ 3500

In Stock


GBI Research, the leading business intelligence provider, has released its latest research, “Critical Care Market to 2019 - Growth from Factor Concentrates, New Indications and Increasing Demand for Albumin in Asia-Pacific”. The report provides in-depth analysis of the drivers and barriers that affect the global critical care market. The report has been compiled using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by GBI Research’s team of industry experts. 

The report analyzes the markets for factor XIII concentrates, fibrinogen concentrates, albumins, antithrombins and prothrombin complex concentrates in the US, the top five countries of Europe (the UK, Germany, France, Italy and Spain), and Japan. The report does also provide an overview on Asia-Pacific countries, including China, India and Australia. The report provides an overview of major marketed products in critical care market along with treatment usage patterns, average annual cost of therapy and market forecast to 2019 for key geographical markets, as well as for leading therapeutic segments. 

The report also provides information on the Research and Development (R&D) product pipeline and explores the competitive landscape, including the provision of profiles for major players in the critical care market. Finally, the report includes analysis of Mergers and Acquisitions (M&A) activity in the critical care market. GBI Research’s analysis indicates that the global critical care market is still an untapped market, with a small number of players accounting for a major proportion of the overall market. The market grew at a very slow growth rate between 2006 and 2012, possibly due to the lac of availability of many of the products in certain markets, especially in the US. 

GBI Research estimates that the overall critical care therapeutics market was worth $2.3 billion in 2012, having grown in size at a CAGR of 11% from $1.2 billion in 2006. The market is expected to grow at a CAGR of 5% to reach $3.2 billion in 2019. The double-digit market growth registered between 2006 and 2012 can be attributed primarily to the increased demand for and cost of albumin, as well as the approval and launch of new products. The growth of the overall critical care market during the forecast period is expected to be largely due to an increasing preference in the market for factor concentrates such as Riastap, Corifact, rFXIII (which has been launched in the EU and is expected to be launched in the US later this year), the expanded indication for Antithrombin (AT) III and factor concentrates, and rising demand for albumin from countries in the Asia-Pacific region. Stagnant innovations, a low prevalence rate and the consequent limited availability of patients are some of the factors impeding the growth of the critical care market.

Scope

  • Data and analysis regarding the critical care market in leading geographical locations – the US, the UK, Germany, France, Italy, Spain, and Japan and Asia-Pacific countries, including India, China and Australia. 
  • Annualized market data for the critical care market, including the individual markets for factor XIII concentrate, fibrinogen concentrate, antithrombin, prothrombin complex concentrate and albumin from 2006 to 2012, with forecasts provided up to 2019. 
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, cost of therapy, sales volume, and treatment usage patterns, such as disease population, diagnosis population and prescription population. 
  • Key drivers and restraints that have had a major impact upon the market. 
  • An overview of the competitive landscape of the global critical care market, including benchmarking for leading companies. Some of the key companies studied in this report are CSL, Octapharma, Baxter, Grifols, and LFB. 
  • Key M&A activities that took place in 2010 and 2011 in the critical care market.

Reasons to Buy

  • Align company product portfolios to markets with high growth potential. 
  • Build effective strategies to launch pipeline products, by identifying potential geographical markets. 
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill portfolio gaps. 
  • Develop key strategic initiatives by studying the key strategies of top competitors. 
  • Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication. 
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth. 
  • Reinforce R&D pipelines by identifying new target mechanisms capable of producing first-in-class molecules which are safer and more efficacious
Table of Contents  

1 Table of Contents  
1.1 List of Tables  
1.2 List of Figures  
 
2 Introduction  
 
3 Critical Care Market to 2019 – Global Overview  
 
4 Critical Care Market to 2019 – Geographical Landscape  
4.1 Introduction  
4.2 The US – Critical Care Market  
4.2.1 Revenue  
4.3 Top Five European Countries – Critical Care Market  
4.3.1 Revenue  
4.4 Japan – Critical Care Market  
4.4.1 Revenue  
 
5 Critical Care Market to 2019 – Albumin Market  
5.1 Introduction  
5.2 Marketed Albumin Products  
5.2.1 Buminate  
5.2.2 Zenalb  
5.2.3 Human Albumin Biotest  
5.2.4 AlbuRx  
5.2.5 Albuminar  
5.2.6 Albutein  
5.2.7 Albuked  
5.2.8 Vialebex  
5.2.9 Albunorm  
5.2.10 AlbuRAAS  
5.3 Revenue  
5.4 Cost of Therapy  
5.5 China  
5.5.1 Introduction  
5.5.2 Strict Regulatory Reforms Leading to Tighter Supply  
5.5.3 Fragmented Market Dominated by Overseas Players  
5.5.4 Price of Albumin Likely to Remain High  
5.5.5 Conclusion  
5.6 India  
5.7 Australia  
5.7.1 Introduction  
5.7.2 Rising Albumin Demand  
5.7.3 Australian Albumin Market  
5.8 Market Drivers and Barriers  
5.8.1 Market Drivers  
5.8.2 Market Barriers  
 
6 Critical Care Market to 2019 – Antithrombin Concentrate Market  
6.1 Introduction  
6.1.1 Marketed Antithrombin Concentrate Products  
6.1.2 Revenue  
6.1.3 Geographical Segmentation  
6.1.4 Cost of Treatment  
6.1.5 Treatment Usage Pattern  
6.2 Drivers and Restraints  
6.2.1 Drivers  
6.2.2 Restraints  
 
7 Critical Care Market to 2019 – Fibrinogen Concentrate Market  
7.1 Introduction  
7.2 Marketed Fibrinogen Concentrates  
7.2.1 Haemocomplettan/Riastap  
7.2.2 Clottafact  
7.2.3 Other Marketed Fibrinogen Concentrates  
7.2.4 Revenue  
7.2.5 Geographical Segmentation  
7.3 Market Segmentation  
7.3.1 Cost of Treatment  
7.4 Treatment Usage Pattern  
7.5 Drivers and Barriers  
7.5.1 Drivers  
7.5.2 Barriers  
 
8 Critical Care Market to 2019 – Prothrombin Complex Concentrate Market  
8.1 Introduction  
8.2 Marketed Products  
8.2.1 Beriplex P/N  
8.2.2 Confidex  
8.2.3 Profilnine SD  
8.2.4 Uman Complex DI  
8.2.5 Kaskadil  
8.2.6 Octaplex 500  
8.2.7 Cofact  
8.2.8 Feiba VH  
8.2.9 Bebulin VH  
8.3 Revenue  
8.3.1 Revenue Breakdown  
8.4 Geographical Segmentation  
8.5 Cost of Therapy  
8.5.1 Treatment Usage Pattern  
8.6 Drivers and Restraints  
8.6.1 Drivers  
8.6.2 Barriers  
 
9 Critical Care Market to 2019 – Factor XIII Concentrate Market  
9.1 Introduction  
9.2 Marketed Products  
9.2.1 Fibrogammin / Corifact  
9.3 Revenue  
9.3.1 Geographical Segmentation  
9.3.2 Cost of Treatment  
9.3.3 Treatment Usage Pattern  
9.4 Drivers and Restraints  
9.4.1 Drivers  
9.4.2 Restraint  
 
10 Critical Care Market to 2019 – Research and Development Product Pipeline  
10.1 Introduction  
10.1.1 rFXIII (NovoThirteen)  
 
11 Critical Care Market to 2019 – Competitive Landscape  
11.1 CSL Limited  
11.2 Baxter International Incorporated  
11.3 Grifols, SA  
11.4 Octapharma AG  
11.5 Kedrion SpA  
11.6 Biotest  
11.7 Laboratoire Français de Fractionnement et de Biotechnologies  
11.8 Bio Products Laboratory Limited  
11.9 Sanquin Blood Supply Foundation  
11.10 China Biologic Products, Incorporated  
11.11 Hualan Biological Engineering, Incorporated  
11.12 Shanghai RAAS Blood Products Company, Limited  
 
12 Critical Care Market to 2019 – Strategic Consolidation  
12.1 Grifols Acquisition of Talecris Biotherapeutics in June 2011  
12.2 LFB Biotechnologies Acquisition of GTC Biotherapeutics in December 2010  
12.3 ViroPharma Expands Licensing Agreement with Sanquin Blood Supply Foundation in January 2010  
 
13 Critical Care Market to 2019 – Appendix  
13.1 Market Definitions  
13.2 Abbreviations  
13.3 Bibliography  
13.4 Research Methodology  
13.4.1 Coverage  
13.4.2 Secondary Research  
13.4.3 Primary Research  
13.5 Therapeutic Landscape  
13.5.1 Market  
13.6 Geographical Landscape  
13.7 Pipeline Analysis  
13.8 Competitive Landscape  
13.8.1 Expert Panel Validation  
13.9 Contact Us  
13.10 Disclaimer 

Table 1: Critical Care Market, Global, Revenue ($bn), 2006–2012  
Table 2: Critical Care Market, Global, Revenue Forecast ($bn), 2012–2019  
Table 3: Critical Care Market, US, Revenue ($m), 2006–2012  
Table 4: Critical Care Market, US, Revenue Forecast ($m), 2012–2019  
Table 5: Critical Care Market, Top Five European Countries, Revenue ($m), 2006–2012  
Table 6: Critical Care Market, Top Five European Countries, Revenue Forecast ($m), 2012– 2019  
Table 7: Critical Care Market, Japan, Revenue ($m), 2006–2012  
Table 8: Critical Care Market, Japan, Revenue Forecast ($m), 2012–2019  
Table 9: Critical Care Market, Global, Albumin, Revenue ($m), 2006–2012  
Table 10: Critical Care Market, Global, Albumin, Revenue Forecast ($m), 2012–2019  
Table 11: Critical Care Market, Australia, Albumin Demand (kg), 2004–2012  
Table 12: Critical Care Market, Global, Available Antithrombin Concentrate Products, 2013 Table 13: Critical Care Market, Global, Antithrombin Concentrate, Revenue ($m), 2006–2012  
Table 14: Critical Care Market, Global, Antithrombin Concentrate, Revenue Forecast ($m), 2012–2019  
Table 15: Critical Care Market, Global, Antithrombin Concentrate, Revenue ($m), 2006–2012  
Table 16: Critical Care Market, Global, Antithrombin Concentrate, Revenue Forecast ($m), 2012–2019  
Table 17: Critical Care Market, Global, Antithrombin Cost of Therapy ($), 2006–2012  
Table 18: Critical Care Market, Global, Antithrombin, Cost of Therapy Forecast ($), 2012–2019  
Table 19: Critical Care Market, Global, Antithrombin, Treatment Usage Pattern (‘000), 2006–2012  
Table 20: Critical Care Market, Global, Antithrombin, Treatment Usage Pattern Forecast (‘000),  
2012–2019  
Table 21: Critical Care Market, Global, Fibrinogen Concentrate, Revenue ($m), 2006–2012 Table 22: Critical Care Market, Global, Fibrinogen Concentrate, Revenue Forecast ($m), 2012–2019  
Table 23: Critical Care Market, Global, Fibrinogen Concentrate, Revenue by Country ($m), 2006–2012  
Table 24: Critical Care Market, Global, Fibrinogen Concentrate, Revenue by Country ($m), 2012–2019  
Table 25: Critical Care Market, Global, Fibrinogen Concentrate, Cost of Therapy ($), 2006–2012  
Table 26: Critical Care Market, Global, Fibrinogen Concentrate, Cost of Therapy Forecast ($), 2012–2019  
Table 27: Critical Care Market, Global, Fibrinogen Concentrate, Epidemiology, 2006–2012 Table 28: Critical Care Market, Global, Fibrinogen Concentrate, Epidemiology, 2012–2019 Table 29: Critical Care Market, Global, Fibrinogen Concentrate, Diagnosed Cases, 2006–   2011  
Table 30: Critical Care Market, Global, PCC, Revenue ($m), 2006–2012  
Table 31: Critical Care Market, Global, PCC, Revenue ($m), 2012–2019  
Table 32: Critical Care Market, Global, PCC, Revenue Segmentation ($m), 2006–2012  
Table 33: Critical Care Market, Global, PCC, Revenue Segmentation ($m), 2012–2019  
Table 34: Critical Care Market, Global, PCC, Cost of Therapy ($), 2006–2012  
Table 35: Critical Care Market, Global, PCC, Cost of Therapy ($), 2012–2019  
Table 36: Critical Care Market, Global, PCC, Number of Patients on PCC (‘000), 2006–2012  
Table 37: Critical Care Market, Global, PCC, Number of Patients on PCC (‘000), 2012–2019  
Table 38: Critical Care Market, Global, Factor XIII Concentrate, Revenue ($m), 2006–2012  
Table 39: Critical Care Market, Global, Factor XIII Concentrate, Revenue ($m), 2012–2019  
Table 40: Critical Care Market to 2019, Global, Factor XIII Concentrate, Revenue Segmentation ($’000), 2006–2012  
Table 41: Critical Care Market, Global, Factor XIII Concentrate, Revenue Segmentation ($’000),  
2012–2019  
Table 42: Critical Care Market, Global, Factor XIII Concentrate, Cost of Therapy ($), 2006–2012  
Table 43: Critical Care Market, Global, Factor XIII Concentrate, Cost of Therapy ($), 2012–2019  
Table 44: Critical Care Market, Global, Factor XIII Concentrate, Treatment Usage Pattern, 2006–2012  
Table 45: Critical Care Market, Global, Factor XIII Concentrate, Treatment Usage Pattern, 2012–2019  
Table 46: Critical Care Market, Global, Factor XIII Concentrate, Reported Diagnosed Cases of FXIII Deficient Patients, 2006–2011  
Table 47: Critical Care Market, Product Pipeline by Indication, 2013

Figure 1: Critical Care Market, Global, Revenue Forecast ($bn), 2006–2019  
Figure 2: Critical Care Market, Global, Revenue by Geography (%), 2012  
Figure 3: Critical Care Market, US, Revenue Forecast ($m), 2006–2019  
Figure 4: Critical Care Market, Global, Revenue ($m), 2012  
Figure 5: Critical Care Market, Top Five European Countries, Revenue Forecast ($m), 2006–2019  
Figure 6: Critical Care Market, Japan, Revenue Forecast ($m), 2006–2019  
Figure 7: Critical Care Market, Global, Albumin, Revenue Forecast ($bn), 2006–2019  
Figure 8: Critical Care Market, Global, Albumin, Average Price ($), 1998–2012  
Figure 9: Critical Care Market, Australia, Albumin Demand (kg), 2004–2012  
Figure 10: Critical Care Market, Global, Albumin, Drivers and Restraints, 2012  
Figure 11: Critical Care Market, Global, Antithrombin Concentrate, Revenue Forecast ($m),2006–2019  
Figure 12: Critical Care Market, Global Antithrombin Market Breakup (%), 2012  
Figure 13: Critical Care Market, Global, Antithrombin Concentrate, Revenue Forecast ($m),2006–2019  
Figure 14: Critical Care Market, Global, Antithrombin, Cost of Therapy Forecast ($), 2006–2019  
Figure 15: Critical Care Market, Global, Antithrombin, Treatment Usage Pattern Forecast (‘000),  
2006–2019  
Figure 16: Critical Care Market, Global, Antithrombin, Drivers and Restraints, 2012  
Figure 17: Critical Care Market, Global, Fibrinogen Concentrate, Revenue Forecast ($m), 2006–2019  
Figure 18: Critical Care Market, Global, Fibrinogen Concentrate, Revenue Segmentation ($m) Forecast, 2006–2019  
Figure 19: Critical Care Market, Global Fibrinogen Concentrate Market Breakup (%), 2012  
Figure 20: Critical Care Market, Global, Fibrinogen Concentrate, Cost of Therapy ($), 2006–2019  
Figure 21: Critical Care Market, Global, Fibrinogen Concentrate, Treatment Usage Pattern,2006–2019  
Figure 22: Critical Care Market, Global Fibrinogen Concentrate Market, Drivers and Restraints, 2012  
Figure 23: Critical Care Market, Global, PCC, Revenue ($m), 2006–2019  
Figure 24: Critical Care Market, Global, PCC Market Breakdown (%), 2012  
Figure 25: Critical Care Market, Global, PCC, Revenue Segmentation ($m), 2006–2019  
Figure 26: Critical Care Market, Global, PCC, Cost of Therapy ($), 2006–2019  
Figure 27: Critical Care Market, Global, PCC, Number of Patients on PCC, 2006–2019  
Figure 28: Critical Care Market, Global PCC Market, Drivers and Restraints, 2012  
Figure 29: Critical Care Market, Global, Factor XIII Concentrate, Revenue ($m), 2006–2019  
Figure 30: Critical Care Market, Global, Factor XIII Concentrate, Revenue Segmentation ($m), 2006–2019  
Figure 31: Critical Care Market, Global, Factor XIII Concentrate Market Breakup (%), 2012  Figure 32: Critical Care Market, Global, Factor XIII Concentrate, Cost of Therapy ($), 2006–2019  
Figure 33: Critical Care Market, Global, Factor XIII Concentrate, Treatment Usage Pattern, 2006–2019  
Figure 34: Critical Care Market, Global, Factor XIII Concentrate Market, Drivers and Restraints, 2012  
Figure 35: GBI Research Market Forecasting Model